XRP News Today: XRP Faces a Pivotal Moment—ETF Excitement Clashes with Technical Skepticism
- XRP's price debate intensifies as spot ETFs attract $410M inflows but fail to push the token above $100, with analysts divided on their long-term impact. - Prominent analyst Moon argues $10+ targets require more than ETF demand, contrasting bullish claims about XRP's utility-driven $1,000 potential. - Ripple's $500M Swell 2025 funding and 11 approved XRP ETFs signal institutional confidence, though historical post-Swell declines persist. - Technical indicators show mixed signals: $2 support retests and p
The
Moon, a well-known XRP analyst, recently pushed back against the view that ETFs alone could send XRP to three-digit values. He pointed out that even reaching $10 would demand more than just ETF-related buying
Institutional participation seems to be a key factor. Ripple’s Swell 2025 event in November 2025 showcased $500 million in funding at a $40 billion valuation, along with plans to expand its RLUSD stablecoin and on-chain lending services
Technical analysis offers a mixed outlook. XRP has revisited important support near $2, which was a resistance level during the 2021 bull run
Regulation continues to be an unpredictable factor. The SEC’s green light for XRP ETFs in late 2025 came after the GENIUS Act was enacted, which clarified rules for payment-oriented digital assets
Although ETFs have not yet led to immediate price surges, their longer-term influence may be seen through greater institutional involvement and reduced XRP availability. The upcoming XRP ETFs from Franklin Templeton and Grayscale, expected to launch at the end of November 2025, could further broaden the range of investment options
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Willdan Group, Inc. (WLDN): A Bull Case Theory

ATRenew Inc. (RERE): A Bull Case Theory

Humana Inc. (HUM): A Bull Case Theory

Wave Life Sciences Ltd. (WVE): A Bull Case Theory
